The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases

Abstract

Hydroxychloroquine, when used to treat patients with rheumatoid arthritis or systemic lupus erythematosus, has been found to reduce cardiovascular disease (CVD). The drug also has been associated with cardiac adverse reactions such as conduction abnormalities. This article reviews the reduction of CVD and the cardiac adverse reactions associated with hydroxychloroquine.